18
|
Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. J Clin Oncol 2017; 35:1041-1048. [PMID: 28113032 DOI: 10.1200/jco.2016.69.2871] [Citation(s) in RCA: 78] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC). Methods Postmenopausal women with HR-positive and node-positive eBC were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day for 5 years or until recurrence of disease. Patients were stratified on the basis of the number of lymph nodes and human epidermal growth factor receptor 2 status. The primary end point was 5-year disease-free survival (DFS), and the key secondary end points were overall survival and safety. Results A total of 4,136 patients were randomly assigned to receive either letrozole (n = 2,061) or anastrozole (n = 2,075). The final analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368 [17.7%]). The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm (hazard ratio, 0.93; 95% CI, 0.80 to 1.07; P = .3150). Exploratory analysis showed similar DFS with letrozole and anastrozole in all evaluated subgroups. The 5-year estimated overall survival rate was 89.9% for letrozole versus 89.2% for anastrozole arm (hazard ratio, 0.98; 95% CI, 0.82 to 1.17; P = .7916). Most common grade 3 to 4 adverse events (> 5% of patients) reported for letrozole versus anastrozole were arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adverse events), hypertension (1.2% v 1.0%), hot flushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%). Conclusion Letrozole did not demonstrate significantly superior efficacy or safety compared with anastrozole in postmenopausal patients with HR-positive, node-positive eBC.
Collapse
Affiliation(s)
- Ian Smith
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Denise Yardley
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Howard Burris
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Richard De Boer
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Dino Amadori
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Kristi McIntyre
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Bent Ejlertsen
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Michael Gnant
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Walter Jonat
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Kathleen I Pritchard
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Mitch Dowsett
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Lowell Hart
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Susan Poggio
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Lisa Comarella
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Herve Salomon
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Barbara Wamil
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| | - Joyce O'Shaughnessy
- Ian Smith and Mitch Dowsett, Royal Marsden Hospital; Institute of Cancer Research, London, United Kingdom; Denise Yardley and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Richard De Boer, Royal Melbourne and Western Hospitals, Melbourne, Australia; Dino Amadori, Istituto Scientifico Romagnolo per lo Studio e la Cura del Tumori Istituto di Ricovero eCura a Carattere Scientifico, Meldola; Lisa Comarella, CROS NT, Verona, Italy; Kristi McIntyre and Joyce O'Shaughnessy, Texas Oncology, US Oncology; Joyce O'Shaughnessy, Baylor University Medical Center; Baylor Charles A. Sammons Cancer Center; The US Oncology Network, Dallas, TX; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Michael Gnant, Medical University of Vienna, Vienna, Austria; Walter Jonat, Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers, FL; Susan Poggio and Barbara Wamil, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Herve Salomon, Novartis Pharma, Rueil-Malmaison, France
| |
Collapse
|